Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787852 · ClinicalTrials.gov registry record · Phase 1
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Brown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00787852: Clinical Trial Phase 1 study, sponsored by Brown University.
NCT00787852 is a Phase 1 study that was terminated before completion, run by Brown University. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00787852, a Phase 1 study, was terminated before completion, sponsored by Brown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and potentially resectable disease.
Primary Outcome
6 patients came off study for toxicity
Interventions
- DRUG Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47
- DRUG Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Why NCT00787852 stopped before completion
NCT00787852 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47 is the first listed.
NCT00787852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00787852 about?
NCT00787852 is a clinical study titled "A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and potentially resectable disease.
What is the current status of trial NCT00787852?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2009-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00787852?
The interventions under investigation include: Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47 (DRUG), Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38 (DRUG).
Who is sponsoring clinical trial NCT00787852?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00787852's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia